German biotechnology company BioNTech announced today (May 10) that it will locate its regional headquarters in Singapore. The company has partnered with Pfizer to develop a Covid-19 vaccine using messenger RNA (mRNA) technology.
The new Singapore headquarters will also include a fully integrated mRNA manufacturing facility and will be supported by the Singapore Economic Development Board (EDB).
This is part of the national strategy to develop the biopharmaceutical industry here, and EBD Chairman Beh Swan Gin said the investment will allow Singapore to “build capacity in an important new therapeutic modality.”
BioNTech co-founder and CEO Ugur Sahin also noted that Singapore enjoys an “excellent business climate” and that opening the regional headquarters is a strategic step for the company. when expanding its global footprint.
BioNTech’s Singapore office is slated to open in 2021, when construction of the manufacturing facility is also slated to begin.
According to the company, the facility could be operational as early as 2023 and create up to 80 jobs in Singapore. However, no information has been released on how much the company has invested in Singapore.
BioNTech said in a press release that the new mRNA manufacturing facility “will take advantage of advanced manufacturing and digital infrastructure,” and will be “equipped to produce a range of new mRNA vaccines and therapies against infectious diseases and cancer ”.
Currently, the Health Sciences Authority (HSA) has assessed that the Pfizer-BioNTech and Moderna COVID-19 vaccines meet standards for safety and efficacy, and these are the two vaccines available in Singapore.
In April, the Ministry of Health announced that those under 45 could soon reserve their vaccination slots. This means that the Covid-19 vaccination is available to all Singaporeans over the age of 16.
Featured Image Credit: World Pharma Today
Our sincere thanks to